Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
PaperCitations, authors & open-access status
Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 281 citations, 2020 year and hybrid oa status.
281
Citations
2020
Year
hybrid
OA Status